Glossary
high-alert medication
A high-alert medication is one that bears a heightened risk of significant harm when it is used in error — insulin, heparin, opioids, concentrated electrolytes. The risk is the harm, not a higher error rate.
A high-alert medication is a drug that carries a heightened risk of causing significant harm when it is used in error. ISMP's own wording adds the sentence that makes the category make sense: mistakes may or may not be more common with these drugs, but the consequences of an error are clearly more devastating. The definition is about severity, not frequency — which is why a drug that is easy to confuse is a different problem from a drug that is dangerous when confused.
The familiar examples are insulin, heparin and other anticoagulants, opioids, concentrated electrolytes such as potassium chloride, neuromuscular blockers, and chemotherapeutic agents. ISMP publishes two lists — one for acute care and one for community/ambulatory settings — and they are not identical, which is the kind of split an exam question likes.
What the category changes in practice is the process, not just the knowledge. High-alert drugs are the ones that attract independent double checks before dispensing, standardized concentrations, limited or segregated stock, and distinct labeling. The distinction a technician has to hold on to is the one between the two error lists: a high-alert drug is dangerous when something goes wrong, while an error-prone abbreviation (QD, U, MS) produces the error in the first place. A question that asks which safeguard belongs where is testing exactly that line.
Taught in
Related terms
- tall man lettering — Tall man lettering puts capital letters into a drug name — glipiZIDE, glyBURIDE — so two look-alike names stop looking alike. FDA and ISMP each publish a list, and they are not the same list.
- NCC MERP — NCC MERP publishes the Index for Categorizing Medication Errors, which sorts errors into categories A to I by outcome: A is a circumstance that could cause an error, B a near miss, and E to I harm.
- beyond-use date — A beyond-use date is the last date a prepared or opened medication may be used. It is set by the pharmacy from USP standards, not by the manufacturer's expiration date on the stock bottle.
Source: PTCB — PTCE Content Outline, effective January 6, 2026 (the KA 1.2 statement "Therapeutic duplications", the KA 2.2 and 2.3 statements on controlled substances and prescription requirements, the KA 4.3 and 4.4 statements on NDC, lot, expiration and returns, and the KA 3.1/3.2 error-prevention statements, quoted verbatim); FDA label and NDC data read through openFDA and DailyMed; ISMP (the high-alert medication definition and the error-prone abbreviation list); USP <795> and <797>; the DEA Pharmacist's Manual (outline accessed 2026-10-03, verbatim; every fact below restates this course's own guides, which carry the per-source citations on their own pages (FDA, ISMP, USP and DEA each publish on its own schedule))